Navigation Links
Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis

fection with Gram-negative bacteria, particularly pulmonary P. aeruginosa, represents the single greatest cause of morbidity and mortality among CF patients. Currently there is no known cure for CF, and the goal of CF therapy is to control symptoms and prevent further lung damage.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia. For more information on Gilead Sciences, please visit the company's website at www.gilead.com or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors. For example, the safety and efficacy data from additional clinical studies may not warrant further development of this compound and initiating and completing clinical trials may take longer or cost more than expected. In addition, future discussions with the FDA may impact the amount of data needed and timelines for review, which may differ materially from Gilead's current projections. Further, the FDA may not approve aztreonam lysine for inhalation for the treatment of CF in the United States, and any marketing approval, if granted, may have significant limitations on its use. If and when regulatory approval is obtained, we will rely on PARI to distribute the device through specialty pharmacies or other distribution channels. If sufficient quantities of this device are not available at the time of a commercial launch or following such a launch, the commercial launch of aztreonam lysine for inhalation could be delayed, and the anticipated contribut
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
5. Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
6. Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:6/3/2015)... Pa. , June 3, 2015  Essential Medical, ... that it has been invited to speak at the ... York city on June 4th.  ... Bore closure system, including a review of first in ...    MANTA closes femoral arterial punctures made ...
(Date:6/3/2015)... 3, 2015 RXi Pharmaceuticals Corporation ... focused on discovering and developing innovative therapeutics, ... ophthalmology, today announced that it received a Notice ... and Trademark Office (USPTO) on its novel, ... "RNA Interference in Ocular Indications," covers methods ...
(Date:6/3/2015)... June 3, 2015  GenVec, Inc. (NASDAQ: GNVC ... David T. Curiel and his team from the ... St. Louis (WUSTL).  Dr. Curiel is the ... Biology Division within the Department of Radiation Oncology. ... team will create modified versions of GenVec,s gorilla adenovectors ...
Breaking Medicine Technology:Essential Medical Inc. Announces Participation in 2015 Jefferies Global Healthcare Conference - NYC 2RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye 2RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye 3RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye 4GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines 2GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines 3GenVec And Washington University at St. Louis Form Collaboration To Discover Targeted Adenovector-Based Therapeutics And Vaccines 4
... WALTHAM, Mass., Sept. 14, 2010 Amylin Pharmaceuticals, Inc. ... (NYSE: LLY ) and Alkermes, Inc. (Nasdaq: ... research findings on BYETTA® (exenatide) injection and the investigational ... presented at the 46th Annual Meeting of the European ...
... Sept. 14 Reportlinker.com announces that a ... its catalogue: Healthcare IT ... Hospital Information Systems and Medical Imaging Information ... Healthcare IT Market Outlook ...
Cached Medicine Technology:BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 2BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 3BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 4BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 5BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 6BYETTA® and BYDUREON™ to be Featured in More Than a Dozen Study Presentations at EASD 2010 7Reportlinker Adds Healthcare IT Market Outlook in China to 2016 - Hospital Information Systems and Medical Imaging Information Systems 2Reportlinker Adds Healthcare IT Market Outlook in China to 2016 - Hospital Information Systems and Medical Imaging Information Systems 3Reportlinker Adds Healthcare IT Market Outlook in China to 2016 - Hospital Information Systems and Medical Imaging Information Systems 4Reportlinker Adds Healthcare IT Market Outlook in China to 2016 - Hospital Information Systems and Medical Imaging Information Systems 5Reportlinker Adds Healthcare IT Market Outlook in China to 2016 - Hospital Information Systems and Medical Imaging Information Systems 6Reportlinker Adds Healthcare IT Market Outlook in China to 2016 - Hospital Information Systems and Medical Imaging Information Systems 7Reportlinker Adds Healthcare IT Market Outlook in China to 2016 - Hospital Information Systems and Medical Imaging Information Systems 8
(Date:6/3/2015)... These are challenging and unpredictable times for ... of digital-first business are rewriting the rules for business ... need for traditional businesses to take on a more ... their services. On top of this there is ... start-ups, to bring new innovation and approaches to business. ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 On May ... Marketing Authorization (MA), effective immediately, which now permits the ... that contain oats as ingredients. The MA is a ... developed. All stakeholders should be aware that, unlike the ... the USA, there are restrictions for gluten-free oat products ...
(Date:6/3/2015)... June 03, 2015 Veatch Consulting Services ... Since they first opened for business in April 2006, ... the needs of their clients. Each and every year ... Dental Consulting is proud to say that they are ... A new feature recently added this year is the ...
(Date:6/2/2015)... (PRWEB) June 03, 2015 BALTIMORE, Md. ... to write a book about wellness after being diagnosed ... she believes that through lifestyle changes which enhance health, ... In “ A Wellspring for Wellness ,” she ... diseases. , This book provides an overview of ...
(Date:6/2/2015)... June 02, 2015 Concorde Career Colleges, ... President and COO. Bell will manage day-to-day operations for ... looking forward to the opportunity to help our Concorde ... said. “I joined Concorde in part due to reports ... highlighted Concorde colleges in Memphis and Portland.” , Bell ...
Breaking Medicine News(10 mins):Health News:Chief Digital Officer of Travelex joins Bayer, Abellio and Just Eat at The Open Mobile Summit London 2Health News:Health Canada Allows For Conditional Use Of Gluten-Free Oats 2Health News:Health Canada Allows For Conditional Use Of Gluten-Free Oats 3Health News:Veatch Consulting Services Is Breaking New Ground in Customer Satisfaction 2Health News:Veatch Consulting Services Is Breaking New Ground in Customer Satisfaction 3Health News:New book offers holistic approach in living with autoimmune diseases 2Health News:New book offers holistic approach in living with autoimmune diseases 3Health News:Concorde Career Colleges Announces New President and COO 2
... study published in the Lancet, researchers had suggested that ... HPV virus might vary from country to country all ... developed against two types of virus that cause cervical ... high-risk HPV infections in Europe than sub-Saharan Africa. ...
... with the new biologic drug adalimumab and methotrexate has ... for people with long-standing rheumatoid arthritis when compared to ... been found to decrease pain and swelling in patients ... ,At the end of the 6-month trial, 43 percent ...
... could be happier than the poor taking into consideration factors ... ,The study was conducted on a group of people ... were questioned regarding their age, total family income and general ... older, race and marital status. ,The analysis of ...
... the state administration of Maharastra who have been under ... floods are now under defensive and are controlling the ... health authorities have reported fewer admissions of new ... such as leptospirosis and dengue showed signs of abating. ...
... men with early stage prostate cancer who make drastic changes ... reverse the progression of their illness say researchers//. The study ... that lifestyle changes may affect the progression of a cancer. ... in men after lung cancer. For the study researchers recruited ...
... latest BMJ said that results of a randomized controlled ... help pregnant smokers quit or cut down had yielded ... mothers//. ,A third of pregnant women smoke and ... support to help them quit. Motivational interviewing - a ...
Cached Medicine News:Health News:Trained Counselors Counseling Pregnant Smokers To Quit May Not Work 2
... The Smith & Nephew ECTRA II ... release the carpal tunnel ligament endoscopically, allowing ... proximal cutting, while minimizing endoscopic lens fogging ... the surgeon complete visualization and control. ECTRA ...
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d...
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d...
... Cross-Screw System offers the surgeon ... for ACL reconstruction utilizing soft ... System provides the latest technology ... comes in Titanium as well ...
Medicine Products: